3,267
Views
11
CrossRef citations to date
0
Altmetric
Real World Evidence

Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States

, , , , , & show all
Pages 202-211 | Received 19 Nov 2020, Accepted 13 Jan 2021, Published online: 24 Feb 2021